Javelin Pharmaceuticals Inc (JAV)

[y3maxx]

...Three reasons why Ereska results delay is a coincidence....

1/

>>> Notice is hereby given that the Annual Meeting of Stockholders (the “Meeting”) of Javelin Pharmaceuticals, Inc., a Delaware corporation, will be held on Tuesday, June 23, 2009 at 9:30 a.m.,

.....3. Considering and voting upon a proposal to amend our 2005 Omnibus Stock Incentive Plan to increase the number of shares available for issuance thereunder from 10,000,000 to 11,000,000;<<<

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001206774%2D09%2D000915%2Etxt&FilePath=%5C2009%5C04%5C30%5C&CoName=JAVELIN+PHARMACEUTICALS%2C+INC&FormType=DEF+14A&RcvdDate=4%2F30%2F2009&pdf=

2/

>>>...on April 29, 2009, the Board determined to reduce the annual base salary of each of Mr. Driscoll and Dr. Carr from $450,000 to $300,000, which change shall be effective for the period from May 1, 2009 through April 30, 2010. In lieu of the foregone cash compensation, the Company granted to each of Mr. Driscoll and Dr. Carr on May 1, 2009 an aggregate of 104,167 deferred stock units (“DSUs”), which DSUs shall have an approximate aggregate face value as of May 1, 2009 equal to each executive’s total foregone cash compensation. The DSUs, each of which consists of one restricted share of the common stock, par value $0.001 per share, of the Company (“Common Stock”), will vest in twelve equal monthly installments beginning on June 1, 2009, and will be distributed in equal installments on May 1, 2010 and May 1, 2011. However, all DSUs will vest and be immediately distributed upon a change-in-control of the Company, and all vested DSUs will be immediately distributed upon a not-for-cause termination of either executive’s employment.

3/

...On April 29, 2009 the Board also approved an amendment to the cash bonus program for named executive officers for 2009 that was described in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on March 3, 2009. Specifically, in lieu of participating in the cash bonus program, Mr. Driscoll and Dr. Carr each elected to receive from the Company a grant of performance options to purchase up to 119,885 shares of Common Stock, which options were granted on May 1, 2009. These options will vest only upon the achievement of the Company’s corporate milestones for its cash bonus program, subject to accelerated vesting upon a change-in-control of the Company, and forfeiture of all of the options upon a not-for-cause termination of either executive’s employment.<<<

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000930413%2D09%2D002450%2Etxt&FilePath=%5C2009%5C05%5C05%5C&CoName=JAVELIN+PHARMACEUTICALS%2C+INC&FormType=8%2DK&RcvdDate=5%2F5%2F2009&pdf=